Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 1/20 | 0.45 |
| ▸ | CA12 | O43570 | 3/20 | 0.34 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.34 |
| ▸ | CA2 | P00918 | 2/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | PTPRB | P23467 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 2/20 | 0.33 |
| ▸ | CA7 | P43166 | 2/20 | 0.33 |
| ▸ | GAA | P10253 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | CNR2 | P34972 | 1/20 | 0.31 |
| ▸ | APLNR | P35414 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2541061 | 1.00 | DGAT1 (0.45) | DGAT1CA12CA14CA2TDP1 | |
| SCHEMBL1374814 | 0.92 | DGAT1 (0.52) | DGAT1CA12CA14CA2TDP1 | |
| SCHEMBL2542864 | 0.82 | KDM4C (0.36) | DGAT1CA12CA14CA2TDP1 | |
| SCHEMBL2537978 | 0.82 | KDM4C (0.36) | DGAT1CA12CA14CA2TDP1 | |
| SCHEMBL17450061 | 0.78 | MMP8 (0.37) | GAAKMT2AKDM4ECNR2ALDH1A1 | |
| Potassium Ion SCHEMBL7713759 | 0.78 | TDP1 (0.36) | DGAT1CA12CA14CA2TDP1 | |
| SCHEMBL16296165 | 0.78 | TDP1 (0.36) | DGAT1CA12CA14CA2TDP1 | |
| Silver SCHEMBL21834857 | 0.78 | TDP1 (0.36) | DGAT1CA12CA14CA2TDP1 | |
| SCHEMBL14152450 | 0.78 | TDP1 (0.36) | DGAT1CA12CA14CA2TDP1 | |
| SCHEMBL4449244 | 0.78 | TDP1 (0.36) | DGAT1CA12CA14CA2TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9227995-B2 | Peptides | Jacobsen, Øyvind (NO) | 2016-01-05 | — | — | US | disclosed |
| US-9227995-B2 | Peptides | Jacobsen, Øyvind (NO) | 2016-01-05 | — | — | US | disclosed |
| US-20110263479-A1 | Peptides | UNIVERSITETET I OSLO (NO) | 2011-10-27 | — | — | US | disclosed |
| US-20110263479-A1 | Peptides | UNIVERSITETET I OSLO (NO) | 2011-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110263479-A1 | Peptides | VIP, NGLY1, NPPA | DGAT1 4788/4885CA12 1559/4885CA14 1334/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.